Diversity of mechanism-based pharmacodynamic models

Drug Metabolism and Disposition

Volumn 31, Issue 5, 2003, Pages 510-518

  Mager, Donald E ^a,b   Wyska, Elzbieta ^a,c   Jusko, William J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ANALYTIC METHOD; CELL PROLIFERATION; CONFERENCE PAPER; DATA ANALYSIS; DRUG EFFECT; DRUG MECHANISM; DRUG TOLERANCE; MATHEMATICAL MODEL; PHARMACODYNAMICS; PRIORITY JOURNAL; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

CELL DIVISION; DRUG TOLERANCE; HUMANS; MODELS, BIOLOGICAL; PHARMACOKINETICS; PHARMACOLOGY; RECEPTORS, DRUG; SIGNAL TRANSDUCTION;

EID: 0037403960     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.31.5.510     Document Type: Conference Paper

References (60)

1. Abelo A, Eriksson UG, Karlsson MO, Larsson H, and Gabrielsson J (2000) A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog. J Pharmacol Exp Ther 295:662-669.
2. Ariens EJ (1954) Affinity and intrinsic activity in the theory of competitive inhibition. Arch Int Pharmacodyn Ther 99:32-49.
3. Ariens EJ (1964) Molecular Pharmacology. Academic Press, New York.
4. Bauer JA and Fung H-L (1994) Pharmacodynamic models of nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Pharm Res (NY) 11:816.
5. Benincosa LJ, Chow FS, Tobia LP, Kwok DC, Davis CB, and Jusko WJ (2000) Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys. J Pharmacol Exp Ther 292:810-816.
6. Bhalla US and Iyengar R (1999) Emergent properties of networks of biological signaling pathways. Science (Wash DC) 283:381-387.
7. Black JW and Leff P (1983) Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 220:141-162.
8. Chakraborty A, Krzyzanski W, and Jusko WJ (1999) Mathematical modeling of circadian cortisol concentrations using indirect response models: comparison of several methods. J Pharmacokinet Biopharm 27:23-43.
9. Cleton A, de Greef HJ, Edelbroek PM, Voskuyl RA, and Danhof M (1999) Application of a combined "effect compartment/indirect response model" to the central nervous system effects of tiagabine in the rat. J Pharmacokinet Biopharm 27:301-323.
10. Dayneka NL, Garg V, and Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21:457-478.
11. Foreman JC and Johansen T (1996) Textbook of Receptor Pharmacology. CRC Press, Boca Raton, FL.
12. Furchgott RF (1955) The pharmacology of vascular smooth muscle. Pharmacol Rev 7:183-265.
13. Gabrielsson J and Weiner D (1997) Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. Swedish Pharmaceutical Press, Stockholm.
14. Gardmark M, Brynne L, Hammarlund-Udenaes M, and Karlsson MO (1999) Interchangeability and predictive performance of empirical tolerance models. Clin Pharmacokinet 36:145-167.
15. Gisleskog PO, Hermann D, Hammarlund-Udenaes M, and Karlsson MO (1998) A model for the turnover of dihydrotestosterone in the presence of the irreversible 5α-reductase inhibitors GI198745 and finasteride. Clin Pharmacol Ther 64:636-647.
16. Gozzi P, Pahlman I, Palmer L, Gronberg A, and Persson S (1999) Pharmacokinetic-pharmacodynamic modeling of the immunomodulating agent susalimod and experimentally induced tumor necrosis factor-α levels in the mouse. J Pharmacol Exp Ther 291:199-203.
17. Hoffman A and Goldberg A (1994) The relationship between receptor-effector unit heterogeneity and the shape of the concentration-effect profile: pharmacodynamic implications. J Pharmacokinet Biopharm 22:449-468.
18. Jusko WJ (1971) Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents. J Pharm Sci 60:892-895.
19. Jusko WJ (1973) A pharmacodynamic model for cell-cycle-specific chemotherapeutic agents. J Pharmacokinet Biopharm 1:175-200.
20. Jusko WJ and Ko HC (1994) Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 56:406-419.
21. Jusko WJ, Ko HC, and Ebling WF (1995) Convergence of direct and indirect pharmacodynamic response models. J Pharmacokinet Biopharm 23:5-8.
22. Katashima M, Yamamoto K, Tokuma Y, Hata T, Sawada Y, and Iga T (1998a) Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans. Eur J Drug Metab Pharmacokinet 23:19-26.
23. Katashima M, Yamamoto K, Tokuma Y, Hata T, Sawada Y, and Iga T (1998b) Pharmacokinetic and pharmacodynamic study of a new nonsteroidal 5-α-reductase inhibitor. 4-[3-[3-[bis(4-isobutylphenyl)methylamino]benzoyl]-1H-indol-1-yl]-butyric acid, in rats. J Pharmacol Exp Ther 284:914-920.
24. Kenakin T (1997) Pharmacologic Analysis of Drug-Receptor Interactions. Lippincott-Raven, Philadelphia.
25. Krzyzanski W and Jusko WJ (1998) Mathematical formalism and characteristics of four basic models of indirect pharmacodynamic responses for drug infusions. J Pharmacokinet Biopharm 26:385-408.
26. Krzyzanski W and Jusko WJ (2001) Indirect pharmacodynamic models for responses with multicompartmental distribution or polyexponential disposition. J Pharmacokinet Biopharm 28:57-78.
27. Krzyzanski W, Ramakrishnan R, and Jusko WJ (1999) Basic pharmacodynamic models for agents that alter production of natural cells. J Pharmacokinet Biopharm 27:467-489.
28. Levy G (1964) Relationship between elimination rate of drugs and rate of decline of their pharmacologic effects. J Pharm Sci 53:342-343.
29. Levy G (1966) Kinetics of pharmacologic effects. Clin Pharmacol Ther 7:362-372.
30. Levy G (1994a) Mechanism-based pharmacodynamic modeling. Clin Pharmacol Ther 56:356-358.
31. Levy G (1994b) Pharmacologic target-mediated drug disposition. Clin PAarmacol Ther 56:248-252.
32. Lew KH, Ludwig EA, Milad MA, Donovan K, Middleton E Jr, Ferry JJ, and Jusko WJ (1993) Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 54:402-414.
33. Li H, Meno-Tetang GM, Chiba K, Arima N, Heining P, and Jusko WJ (2002) Pharmacokinetics and cell trafficking dynamics of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride (FTY720) in cynomolgus monkeys after single oral and intravenous doses. J Pharmacol Exp Ther 301:519-526.
34. Lobo ED and Balthasar JP (2002) Pharmacodynamic modeling of chemotherapeutic effects: application of a transit compartment model to characterize methotrexate effects in vitro. AAPS PharmSci 4:(4) article 42
35. Magee MH, Blum RA, Lates CD, and Jusko WJ (2001) Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race. J Clin Pharmacol 41:1180-1194.
36. Mager DE and Jusko WJ (2001a) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28:507-532.
37. Mager DE and Jusko WJ (2001b) Pharmacodynamic modeling of time-dependent transduction systems. Clin Pharmacol Ther 70:210-216.
38. Mager DE and Jusko WJ (2002) Receptor-mediated pharmacokinetic/pharmacodynamic model of interferon-β1a in humans. Pharm Res (NY) 19:1537-1543.
39. Minami H, Sasaki Y, Saijo N, Ohtsu T, Fujii H, Igarashi T, and Itoh K (1998) Indirect-response model for the time course of leukopenia with anticancer drugs. Clin Pharmacol Ther 64:511-521.
40. Mouton JW, Vinks AA, and Punt NC (1997) Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob Agents Chemother 41:733-738.
41. Movin-Osswald G and Hammarlund-Udenaes M (1995) Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra- and interindividual aspects. J Pharmacol Exp Ther 274:921-927.
42. Nagashima R, O'Reilly RA, and Levy G (1969) Kinetics of pharmacologic effects in man: the anticoagulant action of warfarin. Clin Pharmacol Ther 10:22-35.
43. Pantel K, Loeffler M, Bungart B, and Wichmann HE (1990) A mathematical model of erythropoiesis in mice and rats. Part 4: Differences between bone marrow and spleen. Cell Tissue Kinet 23:283-297.
44. Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, Furst DE, Harter JG, Levy G, Ludden T, Rodman JH et al. (1994) Opportunities for integration of pharmacokinetics, pharmacodynamics and toxicokinetics in rational drug development. J Clin Pharmacol 34:111-119.
45. Perlstein I, Stepensky D, Krzyzanski W, and Hoffman A (2002) A signal transduction pharmacodynamic model of the kinetics of the parasympathomimetic activity of low-dose scopolamine and atropine in rats. J Pharm Sci 91:2500-2510.
46. Preusch PC (2002) What is training in the pharmacological sciences? Mol Interv 2:270-275.
47. Ramakrishnan R, DuBois DC, Almon RR, Pyszczynski NA, and Jusko WJ (2002) Fifth-generation model for corticosteroid pharmacodynamics: application to steady-state receptor down-regulation and enzyme induction patterns during seven-day continuous infusion of methylprednisolone in rats. J Pharmacokinet Pharmacodyn 29:1-24.
48. Sharma A, Ebling WF, and Jusko WJ (1998) Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. J Pharm Sci 87:1577-1584.
49. Sharma A and Jusko WJ (1996) Characterization of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 24:611-635.
50. Sheiner LB, Stanski DR, Vozeh S, Miller RD, and Ham J (1979) Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 25:358-371.
51. Shimada S, Nakajima Y, Yamamoto K, Sawada Y, and Iga T (1996) Comparative pharmacodynamics of eight calcium channel blocking agents in Japanese essential hypertensive patients. Biol Pharm Bull 19:430-437.
52. Sun YN and Jusko WJ (1998) Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. J Pharm Sci 87:732-737.
53. Van der Graaf PH, Van Schaick EA, Visser SA, De Greef HJ, Ijzerman AP, and Danhof M (1999) Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A(1) receptor agonists in rats: prediction of tissue-dependent efficacy in vivo. J Pharmacol Exp Ther 290:702-709.
54. A receptor modulators: vitro-in vivo correlations. J Pharmacol Exp Ther 304:88-101.
55. Wagner JG (1968) Kinetics of pharmacologic response: I. Proposed relationships between response and drug concentration in the intact animal and man. J Theor Biol 20:173-201.
56. Yamamoto K, Abe M, Katashima M, Yamada Y, Sawada Y, and Iga T (1996) Pharmacodynamic analysis of antiplatelet effect of aspirin in the literature - modeling based on inhibition of cyclooxygenase in the platelet and the vessel wall endothelium. Jpn J Hosp Pharm 22:133-141 (in Japanese).
57. Yano Y, Oguma T, Nagata H, and Sasaki S (1998) Application of logistic growth model to pharmacodynamic analysis of in vitro bactericidal kinetics. J Pharm Sci 87:1177-1183.
58. Yates FE (1975) On the mathematical modeling of biological systems: a qualified "pro" in Physiological Adaptation to the Environment (Vernberg FJ ed), Intext Educational Publishers. New York.
59. Zhi JG, Nightingale CH, and Quintiliani R (1988) Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due to Pseudomonas aeruginosa. J Pharmacokinet Biopharm 16:355-375.
60. Zuideveld KP, Maas HJ, Treijtel N, Hulshof J, Van Der Graaf P, Peletier LA, and Danhof M (2001) A set-point model with oscillatory behavior predicts the time course of 8-OH-DPAT-induced hypothermia. Am J Physiol Regul Integr Comp Physiol 281:R2059-R2071.